REGULATORY
MHLW Orders Label Revisions for Anticoagulants, Ondexxya, Tracleer, and More
Japan’s Ministry of Health, Labor and Welfare (MHLW) on November 26 ordered safety-related label revisions for a range of medicines, including five major oral anticoagulants and AstraZeneca’s factor Xa inhibitor reversal agent Ondexxya (andexanet alfa). The affected anticoagulants are Bristol…
To read the full story
Related Article
- Anticoagulants and Other Drugs under PMDA Safety Review
November 4, 2025
REGULATORY
- Japan Pharma Investment Subgroup to Hold 1st Meeting September 18
September 14, 2026
- Japan Formally Joins Project Orbis for Cancer Drug Reviews
September 14, 2026
- MHLW Seeks 20.6 Billion Yen for MCM Stockpiles, Revenue Guarantees
September 14, 2026
- Japan Panel Backs Mandatory Medical Data Sharing by Major Hospitals
September 14, 2026
- Atopic Dermatitis Proactive Therapy to Be Exempt from OTC-Like Drug Charge
September 14, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





